The Most Important Battle in Gene Editing: CRISPR versus TALEN
Despite all the hype, CRISPR is still not in the clinic as a standalone therapy…
Despite all the hype, CRISPR is still not in the clinic as a standalone therapy…
Stimunity, a Parisian biotech, secured a 2M€ seed investment to develop a cancer treatment that…
The FDA approval will give AstraZeneca a competitive advantage in the lung cancer treatment market over Merck…
Christian Schetter’s company, Rigontec, was acquired by MSD last year for nearly half a billion…
Everything you need to know about what checkpoint inhibitors are and why they have caused…
BioNTech will dedicate its huge fundraising to develop personalized cancer immunotherapies using CAR-T, TCR and…
ISA Pharmaceuticals will work together with Regeneron to combine its immunotherapy against cancer induced by…
Data presented at ASH 2017 shows that Servier and Pfizer's UCART19, an allogeneic CAR-T therapy…
The UK grants Immunocore access to a fast-track scheme that will make its immunotherapy IMCgp100…
Avelumab, marketed as Bavencio by Pfizer and Merck, has failed to show better efficacy than…
Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T…
Immunocore, one of the only three European biotech unicorns, has presented Phase I results for…